Artificial hearts will be available on sale for those suffering from critical heart diseases in Europe.
French medical company Carmat has developed the technology and named it Aeson. According to details, it will be available for purchase in the second quarter of 2021. The company has also received approval for it from regulatory authorities.
The 900g machine created to mimic the biological characteristics and functioning of a normal heart is fully capable of facilitating blood circulation in the body.
“The idea behind this heart, which was born nearly 30 years ago, was to create a device which would replace heart transplants, a device that works physiologically like a human heart, one that’s pulsating, self-regulated and compatible with blood,” said Stéphane Piat, Carmat’s CEO.
The device is designed to replace a real heart for years in patients with end-stage biventricular heart failure. For now, it has only been approved as a temporary implant for those awaiting a heart transplant.
According to several estimates, around 2,000 biventricular heart failure patients are on transplant waiting lists across Western Europe.
